1183945-15-4

Basic information

• Product Name: N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine
• Synonyms: N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine
• CAS NO: 1183945-15-4
• Molecular Weight: 292.148
• Mol File: 1183945-15-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine(1183945-15-4)
• EPA Substance Registry System: N-(4-bromo-2-fluorobenzyl)-2,2-dimethoxyethan-1-amine(1183945-15-4)

Safety Data

• Hazardous Substances Data: 1183945-15-4(Hazardous Substances Data)

Upstream product

• 22483-09-6 2,2-dimethoxyethylamine 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1258833-77-0 6-bromo-8-fluoroisoquinoline 
• 1613147-83-3 (R)-5-(2-(tert-butoxycarbonyl)-8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 1613147-79-7 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(8-fluoro-1,2,3,4-tetrahydroisoquinolin-6-yl)pyridin-2-amine 
• 1613147-80-0 N-(4-bromo-2-fluorobenzyl)-N-(2,2-dimethoxyethyl)benzenesulfonamide 

Relevant articles and documents

WDR5 INHIBITORS AND MODULATORS

Isoquinolmone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.